Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.16 - $85.57
Previous CloseN/A
Volume102.39K
Average Volume (3M)1.35M
Market Cap
$10.32B
Enterprise Value$11.79B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)66.4
Beta1.15
Next Earnings
Apr 30, 2025EPS Estimate
0.51Last Dividend Ex-Date
Feb 14, 2025Dividend Yield0.49%
Share Statistics
EPS (TTM)0.98
Shares Outstanding158,087,680
10 Day Avg. Volume1,933,802
30 Day Avg. Volume1,354,523
Standard Deviation0.10
R-Squared0.40
Alpha-0.00361
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.63
Price to Cash Flow (P/CF)30.60
P/FCF Ratio30.60
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.31
Enterprise Value/Ebitda34.46
Forecast
1Y Price Target
$84.71Price Target Upside29.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Customer DemandBio-Techne's Proteins Sciences unit benefited from increasing demand from Cell & Gene Therapy customers, particularly large pharma, with over 500 customers now for TECH’s GMP reagents.
Financial PerformanceBio-Techne reported better than expected financial results for their 2Q25, including revenues of $297.0 million, up 9% year-over-year, and adjusted earnings per share of $0.42 as compared to $0.40 in the prior year period.
Market PositionTECH is carving out a winning position in translational spatial biology with COMET, which could become TECH’s highest pull-through instrument yet.
Bears Say
Operational ChallengesDxG operating margins declined to 12.5% from 18.5% in FY3Q23, primarily driven by Lunaphore dilution.
Regional PerformanceBio-Techne saw strong revenue growth in North America and Europe, growth in other regions through new distributors, and while sales declined in China and Asia, there were signs business was improving in this region due to new government policies.
Revenue ExpectationsCompany management pointed to some big orders in 2Q25 as well as Forex headwinds to temper revenue growth expectations for 3Q25.
---
Ownership Overview
0.22% Insiders
39.66% Mutual Funds
25.60% Other Institutional Investors
10.61% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $61.16 and its highest was $85.57 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $10.32B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Apr 30, 2025 which is in 68 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Feb 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.386 by $0.034.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.316 which represents an annual dividend yield of 0.49%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.51.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 158,087,680 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.42 in its last earnings report, beating expectations of $0.386. Following the earnings report the stock price went up 3.726%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
---
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$84.71 (29.35% Upside)
$84.71 (29.35% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.71%
12-Months-Change
Fundamentals
Return on Equity
7.82%
Trailing 12-Months
Asset Growth
-2.21%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.
---
TECH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in the quarter, with significant growth in core areas and strategic expansion. While there are challenges, particularly in China and foreign exchange impacts, the overall outlook remains positive with expectations of continued growth and recovery in key markets.Read More>---
TECH Net revenue Breakdown
71.69% Protein Sciences
28.16% Diagnostics and Genomics
0.36% Other
---
TECH Stock 12 Month Forecast
Average Price Target
$84.71
▲(29.35% Upside)
Technical Analysis
Best Analysts Covering TECH
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
+2.05%
reiterated a buy rating 16 days ago
Copying Robert Wasserman's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +2.05% per trade.
---